News

Ghent, Belgium, June 1, 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and complex therapies, today announced the appointment of Ariane de Ganck, PhD, as Chief Scientific Officer. This reflects Ardena’s continued focus on scientific excellence across its integrated offering, supporting customers from early development through to later-stage clinical and […]

Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and […]

Somerset, New Jersey, USA – April 15, 2026 – Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces that its new state-of –the-art bioanalytical laboratory in Somerset, New Jersey, is now operational and supporting client studies. The 2,500+ sqft laboratory expands Ardena’s scientific capabilities in North America and provides […]

Ghent, Belgium, April 1, 2026 – Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces its contribution to the advancement of CYRS1542, a novel GSPT1 molecular glue degrader developed by Cyrus Therapeutics, into Phase 1 clinical development. Cyrus Therapeutics received Investigational New Drug (IND) approvals from both the US […]

Ghent, Belgium, 10th March 2026 – PharmaResearch, headquartered in Seongnam, South Korea, has recently received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1 clinical trial of PRD-101, a nano-based anticancer drug candidate. The authorization marks a significant milestone in advancing PRD101 into […]

Ghent, Belgium – March 2, 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO advancing precision medicines, today announces the appointment of Paul Edwards as Chief People Officer. He will lead Ardena’s global people strategy, strengthening organizational capability and supporting the company’s continued international growth.  Paul brings over 30 years of Human Resources leadership experience in complex, science-driven […]

Ghent, Belgium, 29th January 2026 – Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, today announced that it has completed the divestment of its drug substance (API) site in Södertälje, Sweden, to Nanologica AB. The business will operate as a wholly owned subsidiary within the Nanologica Group and will […]

Nouveau Biosciences and Ardena Enter Agreement to Make Clinical Grade Kromastat, an Innovative Nanomedicine for Early Phase Studies Ghent, Belgium, 6th January 2026 – Nouveau Biosciences, a biotechnology company pioneering new approaches to discover novel targeted nanomedicines to improve cancer therapeutics, today announced that it has entered into an agreement with Ardena to manufacture their lead […]

Ghent, Belgium – November 3, 2025 — Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointment of Dipesh Patel as Chief Quality Officer and Peter Rose as Chief Information Officer. These appointments strengthen Ardena’s executive leadership team and reflect its continued focus on quality, compliance, and […]

Peptinovo Biopharma Selects Ardena as Manufacturing Partner to Advance Its Novel Cancer Nanotechnology Toward Clinical Trials Ghent, Belgium, 16th October 2025 – Peptinovo Biopharma, a biotechnology company pioneering targeted cancer therapies through its proprietary PALM™ nanotechnology, today announced a strategic manufacturing partnership with Ardena, a specialist pharmaceutical contract development and manufacturing organization (CDMO) and bioanalytical […]

Ghent, Belgium, 21st August 2025 Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, today announced a strategic partnership with MAXONA Pharmaceuticals, a clinical-stage pharmaceutical company committed to developing the next generation of therapies to help patients maximize life. The collaboration will support the development and manufacturing of MAX-001, […]

Ghent, Belgium, 13th June 2025 A suite of nanoparticle-based immunotherapies developed by Topas Therapeutics has successfully progressed into clinical trials, supported end-to-end regarding Chemistry, Manufacturing, and Control (CMC) by Ardena, a specialist partner in the development and manufacturing of complex formulations and precision medicines. Topas Therapeutics, based in Hamburg, Germany, is pioneering a highly differentiated […]